BrainChip (BRN) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
11 May, 2026Opening remarks and agenda
Acknowledgement of traditional custodians and welcome to attendees, both in-person and virtual.
Introductions of board members, executives, and auditors; confirmation of quorum and meeting procedures.
Explanation of voting and Q&A processes for both in-person and online participants.
Reflected on the inspiration, creation, and future direction of Akida, emphasizing ongoing innovation and vision for edge AI.
Outlined the agenda to review historical AI evolution, product viability, and strategic positioning.
Board and executive committee updates
Presentations from the founder, CEO, and non-executive director highlighted the company's evolution, strategic vision, and leadership continuity.
Board composition and re-election of directors were addressed, with unanimous recommendations for key board members.
Strategic initiatives and plans
Expansion from technology provider to full system provider, focusing on silicon, modules, and reference designs.
Deliberate targeting of defense, aerospace, wearables, medical, and industrial sectors for commercial growth.
Launch of developer hub, Akida Cloud, and partnerships with global distributors to broaden market reach.
Announced expansion of product offerings, including AKD1500, Akida 2x/3x, AKD2500, and AKD3500, with supporting models, reference designs, and IP.
Emphasized the importance of complete hardware and software solutions, including the MetaTF development platform.
Latest events from BrainChip
- Edge AI growth accelerates with neuromorphic innovation and expanding industry adoption.BRN
Investor update - Edge AI growth and AKD1500 chip sales drive new partnerships, with cash at $20.3M.BRN
Q2 2026 - Revenue up 19% but net loss widened as R&D and operating costs rose; AKD1500 production milestone achieved.BRN
H1 2026 - AGM focused on product innovation, commercial growth, and shareholder engagement challenges.BRN
AGM 2025 - Cash outflows improved, R&D consolidated, and new collaborations drive commercialization efforts.BRN
Q2 2024 - Revenue up 72% and net loss reduced, with strong capital raises and edge AI focus for 2025.BRN
H2 2024 - Revenue up 374% to $1.89M, net loss narrows, AKD1500 enters production, capital base strengthened.BRN
H2 2025 - Cash position strengthened and new partnerships drive momentum for neuromorphic AI products.BRN
Q4 2025 - Cash balance rose to $13.9M as AKD1500 enters volume production, backed by new capital and partnerships.BRN
Q3 2025